A month has gone by since the last earnings report for Prothena (PRTA) . Shares have lost about 1.5% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is Prothena due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Prothena Q1 Earnings Miss Estimates on Higher R&D Expense ...

Prothena Corporation plc (PRTA) announced that Bristol Myers (BMY) has in-licensed exclusive global rights to PRX019, a potential treatment option for certain neurodegenerative diseases. PRX019 is the second candidate that has been in-licensed by Bristol Myers under its existing collaboration agreement with PRTA. Prothena anticipates initiating an early-stage study of the candidate by the end of 2024. Bristol Myers' decision to exercise its option for the exclusive global license for PRX019 follows the FDA ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q _____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 ______________________________________ PROTHENA CORPORATION PUBLIC LIMITED COM ...

Exhibit 99.1 PRESS RELEASE Prothena Reports First Quarter 2024 Financial Results and Business Highlights DUBLIN, Ireland, May 8, 2024 -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2024 and provided business highlights. "We continued to meaningfully advance our wholly-owned and partnered programs across our protein ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-K ______________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 (Exact name of registrant as specified in its charter) ______________________________________ (State or other jurisdiction of incorporation or organization) Ireland 98-1111119 (I.R.S. Employer Identification No.) 77 S ...

Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Conference Call February 15, 2023 4:30 PM ET Company Participants Mark Johnson - Vice President of Investor Relations Gene Kinney - President and Chief Executive Officer Hideki Garren - Chief Medical Officer Tran Nguyen - Chief Financial Officer and Chief Strategy Officer Brandon Smith - Chief Operating Officer Conference Call Participants Charles Duncan - Cantor Fitzgerald Jay Olson - Oppenheimer Neena Bitritto-Garg - Citi Yasmeen Rahimi - Piper Sandl ...

200 mg n= ~32 (3:1) - ascent-2 • Evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of PRX012 in patients with Alzheimer's disease 16 Anti-α-synuclein Antibody • 10 million patients globally5 Ongoing Phase 2b PADOVA (NCT04777331) • Primary Endpoint: Time to confirmed motor progression event 3-year change from baseline in MDS-UPDRS Part III OFF score7 NNC6019: Potential First-in-Class Treatment for ATTR Amyloidosis Tran Nguyen Chief Strategy Officer and Chief Financial ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 ______________________________________ PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) __________________________________ ...

15 PRX012 0.070a >67b Data represent KD values from SPRa (nM) or IC50 from ELISAb (nM). • How does binding to protofibrils compare? PRX012s Binds Aβ Protofibrils With Very High Affinity SPR Binding Kinetics Greater affinity is driven largely by a slower binding dissociation Culture time 72 hours at 37°C PRX012s facilitates concentration-dependent clearance of pyroglutamate-modified Aβ (N3pE-Aβ) at concentrations that may be relevant for PRX012 clinical exposure PRX012s Promotes Simultaneous Microglia-Mediat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 10-Q _____________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 ______________________________________ PROTHENA CORPORATION PUBLIC LIMITED COMP ...